NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable or Borderline Resectable Pancreatic Cancer

Conditions:   Borderline Resectable Pancreatic Carcinoma;   Resectable Pancreatic Ductal Adenocarcinoma;   Stage 0 Pancreatic Cancer AJCC v8;   Stage I Pancreatic Cancer AJCC v8;   Stage IA Pancreatic Cancer AJCC v8;   Stage IB Pancreatic Cancer AJCC v8 Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Drug: Leucovorin Calcium;   Drug: Losartan Potassium;   Drug: Oxaliplatin;   Radiation: Radiation Therapy;   Procedure: Resection Sponsors:   OHSU Knight Cancer Institute;   Oregon Health and Science University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials